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In a systematic sequencing screen of the coding exons of the X chromosome in 250 families with X-linked mental
retardation (XLMR), we identiﬁed two nonsense mutations and one consensus splice-site mutation in the AP1S2 gene
on Xp22 in three families. Affected individuals in these families showed mild-to-profound mental retardation. Other
features included hypotonia early in life and delay in walking. AP1S2 encodes an adaptin protein that constitutes part
of the adaptor protein complex found at the cytoplasmic face of coated vesicles located at the Golgi complex. The
complex mediates the recruitment of clathrin to the vesicle membrane. Aberrant endocytic processing throughdisruption
of adaptor protein complexes is likely to result from the AP1S2 mutations identiﬁed in the three XLMR-affected families,
and such defects may plausibly cause abnormal synaptic development and function. AP1S2 is the ﬁrst reported XLMR
gene that encodes a protein directly involved in the assembly of endocytic vesicles.
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Mental retardation (MR) has a prevalence of ∼2%–3% in
developed populations and is more common in males
than in females. Mutations in genes on theX chromosome
are known to be a major cause of familial X-linked MR
(XLMR), and the most common cause of XLMR is an ex-
pansion of an unstable trinucleotide repeat in the 5′ UTR
of the FMR1 gene in patients with fragile X syndrome.1
Mutations in 60 other genes have also been implicated in
XLMR.2–4 However, there remains a substantial proportion
of families with XLMR for which a clear causative muta-
tion in a known gene has not yet been found. Each of the
known XLMR genes accounts for a small proportion of
families with nonsyndromic XLMR. The extent of the ge-
netic heterogeneity associated with nonsyndromic XLMR
compromises the search for additional underlying genes
because linkage information from different families can-
not be combined with conﬁdence. As a consequence,
many XLMR-affected families are mapped to large regions
containing substantial numbers of potential disease genes.
As an alternative strategy to positional cloning and to
obviate the requirement for small linkage intervals to
which XLMR genes have beenmapped, we have embarked
on a systematic, high-throughputmutational screenof the
X chromosome in 250 families with multiple cases of MR.
Greater than 90% of these families could not be classiﬁed
as having a known syndrome, although additional clinical
abnormalities often accompanied the mental deﬁcit. At
least one individual from each of these 250 families was
negative for an expansion of the trinucleotide repeat in
the FMR1 gene underlying fragile X syndrome. A screen
of 60 other known syndromic and nonsyndromic XLMR
genes was conducted by sequencing of the coding exons
and splice junctions, and the 250 families are also negative
for mutations in these. All families have been examined
and are free of abnormalities revealed by conventional
karyotype analysis at 500 G-banding resolution.
Our systematic mutational screen of the X chromosome
is currently directed at the coding exons and splice junc-
tions of 737 Vega annotated genes that are being exam-
ined for variants by bidirectional, PCR-based direct se-
Figure 1. Pedigrees of XLMR-affected families with mutations in AP1S2. Individuals with an asterisk carry the mutant allele in each family. Symbols with a dot represent obligate
female carriers. Representative electropherograms of wild type (wt) and mutant sequences are shown below each pedigree.
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Figure 2. a, Schematic representation of the exon structure of AP1S2, with positions of mutations found in XLMR-affected families.
b, Schematic representation of the coding sequence. The clathrin adaptor complex small-chain functional domain is marked, and positions
of mutations are indicated. The dashed arrow indicates the predicted position of the translational stop codon, under the assumption
of exon 3 skipping in family 63.
quencing. Three deleterious mutations in AP1S2 (MIM
603532; GenBank accession number NM_003916.3) on
Xp22.2 were identiﬁed in the 250 families under inves-
tigation (ﬁgs. 1 and 2).
In family 445, previously described by Turner et al.,5
there is a p.Q36X (c.106CrT) nonsense mutation. This
family showed linkage to Xp22, with a LOD score of 4.8.
In family 502 (MRX59), previously described by Carpenter
et al.,6 there is a p.R52X (c.154CrT) nonsense mutation.
Family 502 (MRX59) showed linkage to Xp22, with a LOD
score of 2.4. In family 63 (ﬁg. 3), there is a 4-bp deletion
preceding the splice-acceptor site of exon 3 that results in
the replacement of the invariant A at position 2 with a
T (c.180-5del4). In silico analysis with the use of the splice-
site prediction software NNSPLICE (BDGP: Splice Site Pre-
diction by Neural Network) indicated that this deletion
reduced the strength of the consensus splice-acceptor site
from 94% to 0%. This mutation is likely to cause skipping
of exon 3, which would then introduce a translational
frameshift, resulting in the inclusion of 3 novel aa, with
termination at codon 64. RNA was not available for direct
evaluation of this prediction. Family 63 showed linkage
to Xp22, with a maximum LOD score of 1.9.
Available individuals from each family have been tested
for the relevant mutation, and, in all three families, the
mutation segregates completely with the disease (ﬁg. 1).
In family 63, the mutation was identiﬁed in all four af-
fected males and three obligate females and was absent in
two unaffected males. In family 445, the mutation was
present in ﬁve affected males and eight obligate carriers
and was absent in seven unaffected males. In family 502
(MRX59), all ﬁve affected males and four obligate carrier
females carried the mutation, and the mutation was not
found in the one unaffected male available for study. In
family 445, expression of AP1S2 was investigated in lym-
phocytes derived from an affected male (ﬁg. 4). No ob-
vious difference in expression was identiﬁed in an affected
male harboring the R53Xmutation, compared with a wild-
type control, indicating that nonsense-mediated mRNA
decay does not act on this premature stop codon con-
taining mRNA. However, whether this and the other two
AP1S2 mutations represent partial or complete loss of
function remains to be determined. No missense or syn-
onymous (silent) variants were found in AP1S2 among the
full set of 250 families with XLMR. To evaluate further the
signiﬁcance of the truncating mutations, we sequenced
AP1S2 in 234 unaffectedmales and 246 unaffected females
from the United Kingdom (in total, 726 alleles of AP1S2).
No truncating variants were detected, and no missense or
synonymous changes were observed, which demonstrated
that the level of population variation in this gene is very
low, further substantiating that the observed mutations
in the three families with XLMR are disease causing. The
difference between XLMR cases and controls for truncat-
ing mutations was signiﬁcant ( , by Fisher’s exactPp .02
test).
Clinical details of family 502 (MRX59) and family 445
have been published elsewhere and therefore will not be
further reviewed here.5,6 Family 63 includes four affected
males (ﬁgs. 1 and 3). III-1 was delivered at term following
an emergency cesarean section at 40 wk due to fetal dis-
tress. He was intubated at birth and was noted to have
hypotonia as a neonate. He fed well, smiled appropriately,
and was not thought to be dysmorphic. At age 6 mo, he
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Figure 3. Photographs of the affected males in family 63. a and b, Individual II-7, aged 42 years. c and d, III-4, aged 24 years.
e and f, III-1, aged 23 years. g and h, III-2, aged 11 years.
Figure 4. RT-PCR analysis of the AP1S2 gene on lymphocyte-cell
RNA in the proband from family 445 (blackened square) and a
control individual (unblackened square). PCR ampliﬁcation of
AP1S2 and the esterase D gene (EST D) shows no difference be-
tween affected and unaffected individuals. pUC19/HpaII was used
as a molecular weight marker. Experiments were performed in the
presence () or absence () of reverse transcriptase. gDNA p
genomic DNA.
was noted to be hypotonic, with a bilateral convergent
squint and marked motor delay. He started to walk at age
6 years. At age 7 years, he had his ﬁrst seizure and has
since been maintained on sodium valproate. As an adult,
he lives in a residential home, requires full care, is obsessed
with the washing machine, and spends much of the time
watching the spin dryer. He has no intelligible speech. III-
2 was born following elective cesarean section. His clinical
features were similar to those of his older brother but were
less severe. He started to walk at age 4 years and has de-
veloped simple language. He has attended a special school
and continues to live at home. The family regards him as
the least severely affected of the family members. III-4 was
born at full term (42 wk). Neonatal hypotonia was noted.
He sat at age 3 years and started to walk at age 6 years.
He lives at home, his speech is limited, and he is capable
of performing simple tasks. II-7 lived at home until age
30 years before moving to sheltered housing, where he is
self-caring but needs supervision. He has limited language
but is able to discuss simple concepts. He attends a day-
care center 2–3 d per wk but does not go out alone. He
has had aggressive outbursts.
The phenotypes of the three families with mutations
in AP1S2 are variable but exhibit many similarities, sum-
marized in table 1. All affected males have MR. However,
the degree of intellectual impairment ranges from mild to
profound. Capacity for speech varies from none to simple
but understandable language. None of the affected indi-
viduals have been capable of independent living, although
several have managed in supportive-care homes. Many
have required full-time care, including toileting and dress-
ing. Obsessive behavioral routines have been reported for
members of all three families, and aggressive outbursts
have also been described. Many members of family 445
are microcephalic (head circumference !3rd percentile),
and two members of family 502 (MRX59) have also been
reported to have microcephaly. Members of family 63 had
head circumferences in the normal range. No signiﬁcant
dysmorphic features have been reported for all three fam-
ilies, although a long, thin face is a feature of both families
63 and 445. The obligate female carriers in all three fam-
ilies have normal intelligence.
Of particular note was marked hypotonia at age 6 mo
in all affected members of the three families. All three
families also report signiﬁcant delay in walking but with-
out other consistent features of neurological dysfunction.
In family 63, walking was achieved between ages 4 and 6
years. In family 502 (MRX59), one affected male was re-
ported to have started to walk at age 6 years. In family
445, one individual is reported to have started to walk at
age 8 years. These features appear to be particularly char-
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Table 1. Selected Clinical Findings in Affected Males
from Families with AP1S2 Mutations
Characteristic









Mild 1 2 2
Moderate 2 5 1
Profound 1 0 2
HC (percentile):
!3 0 6 2
3–55 4 1 2
155 0 0 1
Hydrocephalus 0 1 1
Childhood hypotonia:
Absent 0 0 0
Present 4 7 5
Age at walking (years):
1–2 0 1 0
3–4 1 1 4
14 2 3 1
Not known 1 2 0
Speech:
Absent 1 5 3
Minimal 1 2 0
Present 2 0 2
Aggressive outbursts:
Absent 3 2 2
Present 1 5 3
NOTE.—HC p head circumference.
acteristic of the phenotype of AP1S2 mutations. Delayed
walking was reported in 47 (25%) of 190 evaluated fam-
ilies. Moreover, 3 (6%) of 47 families with delayedwalking
have mutations in AP1S2. Hypotonia was an infrequently
reported clinical ﬁnding in the families with XLMR with-
out AP1S2 mutations.
The AP1S2 gene is composed of ﬁve exons and encodes
a small protein of 157 aa, 90% of which make up the
clathrin adaptor complex small-chain domain. The AP1S2
protein is involved in formation of clathrin-coatedvesicles
that form part of a well-characterized system of eukaryotic
membrane protein trafﬁcking (see Edeling et al.7 for re-
view). The system has two major components: clathrin,
which provides structural integrity, and adaptor protein
complexes, which determine selection of the vesicle cargo
and promote clathrin-lattice formation onto the vesicle
membrane.8 There are ﬁve adaptor protein complexes as-
sociated with clathrin (AP1, AP2, AP3, AP4, and AP180),
of which AP1 and AP2 are the best characterized. Both
AP1 and AP2 adaptor complexes are composed of two large
subunits (g and b1 in the AP1 complex), one medium
subunit (m1), and one small sigma subunit (j1, or j).AP1S2
encodes the sigma 2 subunit of the heterotetrameric AP1
adaptor complex. The AP1 complex is preferentially as-
sociated with endosomes and the trans-Golgi network,
whereas the AP2 complex is associated more with the cy-
toplasmic membrane. AP1 binds both YXXf (where X is
any amino acid and f is a large hydrophobic residue) and
[D/E]XXXL[L/I] acidic dileucine motifs found in vesicle
cargo proteins, including transmembrane receptors.7
Aberrant endocytic processing through disruption of
functional AP1 complexes is likely to result from the loss
of function AP1S2 mutations identiﬁed in the three fam-
ilies with XLMR. Such a deﬁcit would plausibly have an
impact on normal synaptic vesicle cycling and, thus, pro-
cessing and trafﬁcking of membrane proteins, including
receptors and ion channels. AP1 has been shown to as-
sociate with synaptophysin, one of the most abundant
synaptic vesicle proteins thought to play an important
role in neurotransmitter release. The cytoplasmic tail re-
gion of synaptophysin interacts with g-adaptin of AP1 in
a yeast two-hybrid system, and these proteins have also
been shown to colocalize in the perinuclear region of cul-
tured hippocampal neurons.9 Interactions between AP1
and the vesicular acetylcholine transporter, responsible for
the transport of acetycholine from the cytosol into syn-
aptic vesicles, have also been reported.10 Disruption of the
AP1 complex viamutations in AP1S2 could feasibly impair
these interactions and disrupt normal neurotransmitter
processing within the synapse. This hypothesis is sup-
ported by Drosophila mutants with deﬁcits in various en-
docytic proteins, including the clathrin assembly protein
SNAP91 (AP180), which have altered synaptic develop-
ment.11 SNAP91, together with the AP1 and AP2 com-
plexes, is critical for clathrin coat assembly under physio-
logical conditions, and it has been suggested that SNAP91
interacts with adaptor protein complexes in regulating the
uncoating of clathrin-coated vesicles.7,12
No previously identiﬁed XLMR gene has been centrally
implicated in the general formation and processing of en-
docytotic vesicles. However, other proteins encoded by
XLMR genes have been involved in the biology of synap-
tic vesicles. GDI1 is a Ras superfamily of small GTPases
guanosine diphosphate (GDP)–dissociation inhibitor in-
volved in vesicle trafﬁcking via regulation of theGDP-GTP
exchange reaction.3 The protein DLG3/SAP102 has been
reported to interact with the exocyst complex and may
assist in the trafﬁcking of N-methyl-D–aspartic acid recep-
tors from the endoplasmic reticulum to the synaptic cell
surface.13 Moreover, SYN1, a known XLMR gene and a
member of the synapsin family, encodes a neuronal phos-
phoprotein that associates with the cytoplasmic surface
of synaptic vesicles.14 Mutations in the clathrin/endocytic
processing system have been reported in other human
diseases. Autosomal recessive mutations in the adaptor
protein ARH lead to defective endocytosis of low-density
lipoprotein receptors in hypercholesterolemia (MIM
603813),15,16 and autosomal recessive mutations in AP3B1
result in Hermansky-Pudlak syndrome type 2 (MIM
203300).17
AP1S2 encodes a predicted protein of only 157 aa. The
presence of three different truncating mutations in such
a small gene, the complete segregation of mutations in
affected individuals, the absence of the truncatingvariants
in unaffected controls, and the previous evidence of link-
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age to this region of the X chromosome strongly indicate
that AP1S2 is the gene responsible for MR in these three
families. The small size of the gene may allow relatively
straightforward introduction into diagnostic testing. To
our knowledge, AP1S2 is the ﬁrst reported XLMR gene
encoding a protein that is directly involved in vesicle as-
sembly and processing.
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